Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy B Jones

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
The Lancet. Oncology|September 7, 2016
Patient safety and institutional review boards in multi-institutional dose escalation or expansion trialsRoy B Jones
Cancer Treatment and Research|December 17, 2002
Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agentsRoy B Jones
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
Overcoming methodological weakness in dose-intense alkylating agent studies through pharmacologyRoy B Jones
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
DNA-binding agentsYago Nieto, Roy B Jones
Current Opinion in Oncology|April 13, 2004
High-dose chemotherapy for breast cancer: is another look warranted?Yago Nieto, Roy B Jones, Elizabeth J Shpall
Current Oncology Reports|September 15, 2012
Overview of electronic data sharing: why, how, and impactRoy B Jones, Dianne Reeves, Charles S Martinez
Springer Seminars in Immunopathology|September 16, 2004
Stem-cell transplantation for the treatment of advanced solid tumorsYago Nieto, Roy B Jones, Elizabeth J Shpall
American Journal of Clinical Oncology|June 1, 2005
Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapyYago Nieto, Elizabeth J Shpall, Scott I Bearman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 9, 2016
Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid MalignanciesKeiji Shinozuka, Hongwei Tang, Roy B Jones, et al.
The Annals of Pharmacotherapy|July 7, 2011
Busulfan and metronidazole: an often forgotten but significant drug interactionAlison M Gulbis, Kirk S Culotta, Roy B Jones, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
The Lancet. Oncology|September 7, 2016
Patient safety and institutional review boards in multi-institutional dose escalation or expansion trialsRoy B Jones
Cancer Treatment and Research|December 17, 2002
Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agentsRoy B Jones
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2004
Overcoming methodological weakness in dose-intense alkylating agent studies through pharmacologyRoy B Jones
Cancer Chemotherapy and Biological Response Modifiers|April 22, 2003
DNA-binding agentsYago Nieto, Roy B Jones
Current Opinion in Oncology|April 13, 2004
High-dose chemotherapy for breast cancer: is another look warranted?Yago Nieto, Roy B Jones, Elizabeth J Shpall
Current Oncology Reports|September 15, 2012
Overview of electronic data sharing: why, how, and impactRoy B Jones, Dianne Reeves, Charles S Martinez
Springer Seminars in Immunopathology|September 16, 2004
Stem-cell transplantation for the treatment of advanced solid tumorsYago Nieto, Roy B Jones, Elizabeth J Shpall
American Journal of Clinical Oncology|June 1, 2005
Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapyYago Nieto, Elizabeth J Shpall, Scott I Bearman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 9, 2016
Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid MalignanciesKeiji Shinozuka, Hongwei Tang, Roy B Jones, et al.
The Annals of Pharmacotherapy|July 7, 2011
Busulfan and metronidazole: an often forgotten but significant drug interactionAlison M Gulbis, Kirk S Culotta, Roy B Jones, et al.
Pageof 7